Drug Trial Radar · NCT01243424
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Jan 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,103
Actual
Start
Nov 11, 2010
Primary completion
Aug 21, 2018
Study completion Aug 21, 2018
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Nov 18, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with linagliptin in patients with type 2 diabetes at elevated cardiovascular risk receiving usual care, and compare outcome against glimepiride.
Conditions
- Diabetes Mellitus, Type 2
Interventions
linagliptinDrug
linagliptin tablets 5mg QD
glimepirideDrug
glimepiride over-encapsulated tablet 1-4 mg QD
linagliptin placeboDrug
linagliptin placebo
glimepiride placeboDrug
glimepiride placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The First 3-point Major Adverse Cardiovascular Events (3P-MACE)Time frame: From randomization until individual day of trial completion, up to 432 weeks
Locations
613 sites in 43 countries. Site status is shown where the registry gives one.
North Alabama Research Center, LLC
Athens, Alabama
Alabama Internal Medicine, PC
Birmingham, Alabama
Cahaba Research, Inc.
Birmingham, Alabama
Internal Medicine Center, LLC
Mobile, Alabama
Diagnostic and Medical Clinic
Mobile, Alabama
Extended Arm Physicians, Inc.
Montgomery, Alabama
Office of Dr. Terence T. Hart MD
Tuscumbia, Alabama
Advanced Clinical Research
Pell City, Alaska
Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC
Mesa, Arizona
Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC
Mesa, Arizona
Genova Clinical Research
Tucson, Arizona
Quality of Life Medical & Research Center
Tucson, Arizona
Northeast Arkansas Baptist Clinic
Jonesboro, Arkansas
Medical Investigations, Inc
Little Rock, Arkansas
Aureus Research, Inc
Little Rock, Arkansas
Desert Oasis Healthcare
Bermuda Dunes, California
Edinger Medical Group and Research Center
Fountain Valley, California
Clinical Trials of St. Jude Heritage Med. Group
Fullerton, California
Long Beach Center for Clinical Research
Long Beach, California
Office of Dr. Richard S. Cherlin
Los Gatos, California
Providence Clinical Research
North Hollywood, California
Chaparral Medical Group, Inc
Pomona, California
ARI Clinical Trials, Inc
Redondo Beach, California
San Diego Sports Medicine and Family Health Center
San Diego, California
West Coast Research, LLC
San Ramon, California
University of California Los Angeles
Sylmar, California
Metabolic Institute of America
Tarzana, California
Matrix Research Institute
Tustin, California
Orange County Research Center
Tustin, California
Westlake Medical Research
Westlake Village, California
Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC
Colorado Springs, Colorado
Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC
Colorado Springs, Colorado
East Coast Medical Associates
Boca Raton, Florida
Todd Kazdan, DO Family Practice
Davie, Florida
Century Clinical Research, Inc
Daytona Beach, Florida
Doral Research Center
Doral, Florida
Riverside Clinical Research
Edgewater, Florida
Alan Graff, MD, PA
Fort Lauderdale, Florida
M & O Clinical Research, LLC
Fort Lauderdale, Florida
Eastern Research
Hialeah, Florida
Showing 40 of 613 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.